Overview

StairMed Technology is one of China’s most well-funded implantable BCI startups, securing 350 million yuan ($48 million) in Series B funding in February 2025 — the largest single funding round for any Chinese brain-computer interface company. Founded in 2021 and based in Shanghai, the company develops minimally invasive implantable neural interfaces.

Technology

StairMed focuses on flexible brain-controlled implant technology, offering what the company describes as the only flexible neural interface product in China with world-leading electrode design. The approach prioritizes biocompatibility and long-term stability through materials and form factors that reduce chronic tissue response.

Clinical Progress

The company has conducted first-in-human BCI-related investigator-initiated trials, advancing toward regulated clinical studies. The Series B capital is earmarked for accelerating clinical trials, expanding R&D capabilities, and building a dedicated manufacturing facility.

Market Context

StairMed operates in a rapidly growing Chinese BCI ecosystem supported by the government’s 11.6 billion yuan ($165 million) brain science fund and national policy targeting BCI breakthroughs by 2027. The company competes with NeuroXess and NeuCyber in the Chinese implantable BCI space.